Top

Osteoporosis International

Published in:

Open Access 01-01-2012 | Original Article

A reappraisal of generic bisphosphonates in osteoporosis

Authors: J. A. Kanis, J.-Y. Reginster, J.-M. Kaufman, J.-D. Ringe, J. D. Adachi, M. Hiligsmann, R. Rizzoli, C. Cooper

Published in: Osteoporosis International | Issue 1/2012

Abstract

Summary

The competitive price of generic bisphosphonates has had a marked effect on practice guidelines, but an increasing body of evidence suggests that they have more limited effectiveness than generally assumed.

Introduction

The purpose of this study is to review the impact of generic bisphosphonates on effectiveness in the treatment of osteoporosis.

Methods

This study is a literature review.

Results

A substantial body of evidence indicates that many generic formulations of alendronate are more poorly tolerated than the proprietary preparations which results in significantly poorer adherence and thus effectiveness. Poorer effectiveness may result from faster disintegration times of many generics that increase the likelihood of adherence of particulate matter to the oesophageal mucosa. Unfortunately, market authorisation, based on the bioequivalence of generics with a proprietary formulation, does not take into account the potential concerns about safety. The poor adherence of many generic products has implications for guideline development, cost-effectiveness and impact of treatment on the burden of disease.

Conclusions

The impact of generic bisphosphonates requires formal testing to re-evaluate their role in the management of osteoporosis.

Kanis JA, Johnell O (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229–238PubMedCrossRef

Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359:2018–2026PubMedCrossRef

Compston J, Cooper A, Cooper C et al (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:105–108PubMedCrossRef

Van Staa TP (2006) The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 79:129–137PubMedCrossRef

Compston JE (2007) Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis. Curr Rheumatol Rep 9:78–84PubMedCrossRef

Papaioannou A, Morin S, Cheung A et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864–1873PubMedCrossRef

McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340PubMedCrossRef

Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765PubMedCrossRef

Delmas PD (2008) Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom 11:325–338PubMedCrossRef

10.

Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468PubMedCrossRef

11.

Reginster JY, Seeman E, De Vernejoul MC et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocrinol Metab 90:2816–2822PubMedCrossRef

12.

Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541PubMedCrossRef

13.

Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRef

14.

Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.PG. JAMA 282:11344–11352CrossRef

15.

Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809PubMedCrossRef

16.

Agence Française de Sécurité Sanitaire des Produits de Santé (2006) 19/01/2006 - Traitement médicamenteux de l’ostéoporose post-ménopausique - recommandations de bonne pratique. http://www.afssaps.fr/content/search?SearchText=osteoporose&ok=Valider

17.

Braun J, Pfeilschifter J (2010) Osteoporosis diagnosis and therapy according to the 2010 guidelines. Z Rheumatol 69:327–339PubMedCrossRef

18.

Pfeilschifter J (2006) 2006 DVO-guideline for prevention, diagnosis, and therapy of osteoporosis for women after menopause, for men after age 60 executive summary guidelines. Exp Clin Endocrinol Diabetes 114:611–622PubMed

19.

Adami S, Bertoldo F, Brandi ML et al (2009) Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo 61:260–284PubMed

20.

Royal College of Physicians (1999) Osteoporosis: clinical guidelines for the prevention and treatment. Royal College of Physicians, London

21.

Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster J-Y, Borgstrom F, Rizzoli R, On behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428PubMedCrossRef

22.

Strom O, Borgstrom F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries–an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047–1061PubMedCrossRef

23.

Kanis J, McCloskey E, Jönsson B, Cooper A, Ström O, Borgström F (2010) An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Arch Osteoporos 5:19–48CrossRef

24.

Kanis JA, Adams J, Borgstrom F, Cooper C, Jonsson B, Preedy D, Selby P, Compston J (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4–15PubMedCrossRef

25.

Zethraeus N, Borgstrom F, Strom O, Kanis JA, Jonsson B (2007) Cost-effectiveness of the treatment and prevention of osteoporosis–a review of the literature and a reference model. Osteoporos Int 18:9–23PubMedCrossRef

26.

Borgstrom F, Johnell O, Kanis JA, Oden A, Sykes D, Jonsson B (2004) Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 22:1153–1165PubMedCrossRef

27.

Royal College of Physicians and Bone and Tooth Society of Great Britain (2000) Update on pharmacological interventions and an algorithm for management. Royal College of Physicians, London

28.

National Institute for Health and Clinical Excellence (2010) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. London, NICE. November 2010

29.

González M, Guañabens GN, Gómez C et al (2008) (Comité de Redacción, en representación del Comité de Expertos de la SEIOMM para la elaboración de las Guías). Practice guidelines for postmenopausal, steroid-induced and male osteoporosis. Spanish Society for Bone and Mineral Research. Rev Clin Esp 208(suppl 1):1–24

30.

Figueras J, McKee M, Lessof S et al (2008) Health systems, health and wealth: assessing the case for investing in health systems. World Health Organization 2008 and World Health Organization, on behalf of the European Observatory on Health Systems and Policies. Available at: http://www.euro.who.int. Accessed 7 May 2011

31.

Johnston A (2010) Challenges of therapeutic substitution of drugs for economic reasons: focus on CVD prevention. CMRO 26:871–878CrossRef

32.

Andersson K, Bergström G, Petzold MG et al (2007) Impact of a generic substitution reform on patients’ and society’s expenditure for pharmaceuticals. Health Policy 81:376–383PubMedCrossRef

33.

Hakonsen HH, Eilertsen M, Borge H, Toverud EL (2009) Generic substitution: additional challenge for adherence in hypertensive patients? CMRO 25:2515–2521CrossRef

34.

EMEA (1998) Guideline on the investigation of bioequivalence. CPMP/EWP/QWP/1401/98 Rev.1. Available at: http://www.emea.europa.eu/htms/human/humanguidelines/efficacy.htm. Accessed 7 May 2011

35.

Lufkin EG, Argueta R, Whitaker MD et al (1994) Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 4:320–322PubMedCrossRef

36.

De Groen PC, Lubbe DF, Hirsch LJ et al (1996) Esophagitis associated with the use of alendronate. N Engl J Med 335:1016–1021PubMedCrossRef

37.

Naylor G, Davies MH (1996) Oesophageal stricture associated with alendronic acid. Lancet 348:1030–1031PubMedCrossRef

38.

Kane S, Borisov N, Brixner D (2004) Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study. Am J Manag Care 10:S216–S228

39.

Wysowski DK (2010) Oral bisphosphonates and oesophageal cancer. BMJ 341:c4506PubMedCrossRef

40.

Perkins AC, Blackshaw DE, Hay PD et al (2008) Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects. Clin Ther 30:834–844PubMedCrossRef

41.

Gold DT, Silverman S (2006) Review of adherence to medicationsfor the treatment of osteoporosis. Curr Osteoporos Rep 4:21–27PubMedCrossRef

42.

Rossini M, Bianchi G, Di MO et al (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914–921PubMedCrossRef

43.

Strampel W, Emkey R, Civitelli R (2007) Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 30:755–763PubMedCrossRef

44.

Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21:1943–1951PubMedCrossRef

45.

Sheehy O, Kindundu CM, Barbeau M, LeLorier J (2009) Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int 20:1369–1376PubMedCrossRef

46.

Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645–1652PubMedCrossRef

47.

Halkin H, Dushenat M, Silverman B (2007) Brand versus generic alendronate: gastrointestinal effects measured by resource utilization. Ann Pharmacother 41:29–34PubMed

48.

Sheehy O, Kindundu C, Barbeau M, LeLorier J (2009) Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures. Osteoporos Int 20:1583–1594PubMedCrossRef

49.

Grima DT, Papaioannou A, Thomson MF, Pasquale MK, Adachi JD (2008) Greater first year effectiveness drives favourable cost-effectiveness of brand risedronate versus generic or brand alendronate: modelled Canadian analysis. Osteoporos Int 19:687–697PubMedCrossRef

50.

Ringe JD, Möller G (2009) Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 30:213–221PubMedCrossRef

51.

Ensrud KE, Barrett-Connor EL, Schwartz A et al (2004) Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 19:1259–1269PubMedCrossRef

52.

Neele SJ, Evertz R, Valk-De Roo G, Roos JC, Netelenbos JC (2002) Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 30:599–603PubMedCrossRef

53.

Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965–968PubMedCrossRef

54.

Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008PubMedCrossRef

55.

Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928PubMedCrossRef

56.

Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022PubMedCrossRef

57.

Olszynski WP, Adachi J, Davison J, Davison KS (2010) Disintegration times of brand and generic bisphosphonates available in Canada. J Bone Miner Res 25:S125

58.

Epstein S, Cryer B, Ragi S et al (2003) Disintegration/dissolution profiles of copies of Fosamax (alendronate). Curr Med Res Opin 19:781–789PubMedCrossRef

59.

Dansereau RJ, Crail DJ, Perkins AC (2008) In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications. Curr Med Res Opin 24:1137–1145PubMedCrossRef

60.

Dansereau RJ, Crail DJ, Perkins AC (2009) In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US. Curr Med Res Opin 25:449–452PubMedCrossRef

61.

Almeida S, Almeida A, Filipe A et al (2006) In vitro disintegration and dissolution and in vivo bioequivalence of two alendronate once-weekly formulations. Arzneimittelforschung 56:84–89PubMed

62.

Lamprecht G (2009) In vitro determination of the release of alendronic acid from alendronate tablets of different brands during deglutition. J Pharm Sci 98:3575–3581PubMedCrossRef

63.

Perkins AC, Wilson CG, Frier M, Vincent RM, Blackshaw PE, Dansereau RJ, Juhlin KD, Bekker PJ, Spiller RC (1999) Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations. Int J Pharm 186:169–175PubMedCrossRef

64.

Epstein S, Geusens P, Fisher JE et al (2005) Disintegration and esophageal irritation profiles of alendronate formulations: implications for clinical safety and efficacy. J Applied Res 5:253–264

65.

Shakweh M, Bravo-Osuna I, Ponchel G (2007) Comparative in vitro study of oesophageal adhesiveness of different commercial formulations containing alendronate. Eur J Pharm Sci 31:262–270PubMedCrossRef

66.

Department of Heath and Ageing (2011) Australian public assessment report for alendronic acid. Australian Government, Department of Health and Ageing Therapeutics Goods Administration. Submission PM-01135-3-5, February 2011

67.

Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 286:202–210CrossRef

68.

Hiligsmann M, Gathon HJ, Bruyère O, Ethgen O, Rabenda V, Reginster JY (2010) Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health 13:394–401PubMedCrossRef

69.

Strom O, Borgstrom F, Kanis JA, Jonsson B (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20:23–34PubMedCrossRef

Title: A reappraisal of generic bisphosphonates in osteoporosis
Authors: J. A. Kanis
J.-Y. Reginster
J.-M. Kaufman
J.-D. Ringe
J. D. Adachi
M. Hiligsmann
R. Rizzoli
C. Cooper
Publication date: 01-01-2012
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 1/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-011-1796-6

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

A reappraisal of generic bisphosphonates in osteoporosis

Abstract

Summary

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Impact of a centralized osteoporosis coordinator on post-fracture osteoporosis management: a cluster randomized trial

Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES)

Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists

Pattern of use of DXA scans in men: a cross-sectional, population-based study

High fracture probability with FRAX® usually indicates densitometric osteoporosis: implications for clinical practice

GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates